Kanada - angličtina - Health Canada

avir pharma inc. - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - miscellaneous therapeutic agents

Spojené štáty - angličtina - NLM (National Library of Medicine)

huvepharma, inc - flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400), phenol (unii: 339ncg44tv) (phenol - unii:339ncg44tv) - only for intravenous use in beef and dairy cattle. not for use in dry dairy cows and veal calves. for intravenous and intramuscular use in horses. before using this drug, read package outsert for complete product information. only for intravenous use in beef and dairy cattle. not for use in dry dairy cows and veal calves. for intravenous and intramuscular use in horses. indications    horse: flu-nix™ (flunixin meglumine injection) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. it is also recommended for the alleviation of visceral pain associated with colic in the horse.    cattle: flu-nix™ (flunixin meglumine injection) is indicated for the control of pyrexia associated with bovine respiratory disease, endotoxemia and acute bovine mastitis. flu-nix™ (flunixin meglumine injection) is also indicated for the control of inflammation in endotoxemia. contraindications    horse: there are no known contraindications t

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

reach pharmaceuticals pty ltd - fosaprepitant dimeglumine, quantity: 245.3 mg (equivalent: fosaprepitant, qty 150 mg) - injection, powder for - excipient ingredients: lactose; polysorbate 80; hydrochloric acid; sodium hydroxide; disodium edetate - fosaprepitant msn, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of:,? highly emetogenic cancer chemotherapy (see section 4.2 dose and method of administration),? moderately emetogenic cancer chemotherapy (see section 4.2 dose and method of administration).

Írsko - angličtina - HPRA (Health Products Regulatory Authority)

bayer limited - meglumine; sodium hydroxide ; sodium amidotrizoate - solution for infusion - 30 percent weight/volume - diatrizoic acid

Singapur - angličtina - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - meglumine amidotrizoate; sodium amidotrizoate - solution - 0.66 g/ml - meglumine amidotrizoate 0.66 g/ml; sodium amidotrizoate 0.1 g/ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

obex medical ltd - meglumine ioxaglate 39.3%{relative} (gives 320mg iodine/ml); sodium ioxaglate 19.65%{relative} - solution for injection - 320 mg/ml - active: meglumine ioxaglate 39.3%{relative} (gives 320mg iodine/ml) sodium ioxaglate 19.65%{relative} excipient: sodium calcium edetate, hydrate water for injection - low osmolar x-ray contrast medium for the opacification of the vascular system, urinary tract, joints and female genital tract. hysterosalpingography

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

obex medical ltd - meglumine gadoterate 377 mg/ml equivalent to to 279.32 mg/ml gadoteric acid (0.5 mmol/ml) - solution for injection - 377 mg/ml - active: meglumine gadoterate 377 mg/ml equivalent to to 279.32 mg/ml gadoteric acid (0.5 mmol/ml) excipient: meglumine water for injection

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine amidotrizoate; sodium amidotrizoate - solution for injection - 260mg/1ml ; 40mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine gadopentetate - solution for injection - .002mmol/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - meglumine gadopentetate - solution for injection - .5mmol/1ml